PIK3CD as a Drug Target and Biomarker: Implications for Cancer Treatment

Target Name: PIK3CD

NCBI ID: G5293

PIK3CD

Other Name(s): IMD14 | Phosphoinositide-3-kinase C | Phosphoinositide-3-kinase, catalytic, delta polypeptide variant p37delta | IMD14A | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta short variant 20 | PI3K | IMD14B | APDS | PI3K-delta | PtdIns-3-kinase subunit p110-delta | ROCHIS | p110delta | PK3CD_HUMAN | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform | ptdIns-3-kinase subunit p110-delta | Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta | phosphoinositide-3-kinase, catalytic, delta polypeptide variant p37delta | PI3-kinase subunit delta | PI3Kdelta | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PtdIns-3-kinase subunit delta | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Phosphoinositide-3-kinase, catalytic, delta polypeptide (PI3K-delta) | Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta | PI3-kinase p110 subunit delta | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (isoform 1) | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta short variant 8 | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta, transcript variant 1 | P110DELTA | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta short variant 8/20 | phosphoinositide-3-kinase C | p110D | PIK3CD variant 1 | phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta

PIK3CD as a Drug Target and Biomarker: Implications for Cancer Treatment

Introduction

PIK3CD (phosphatidylinositol-3-kinase, 尾,未-catenin) is a protein that plays a crucial role in cellular signaling pathways, particularly in the regulation of cell growth, differentiation, and survival. PIK3CD has been identified as a potential drug target and biomarker for cancer treatment due to its unique structure, function, and regulation. In this article, we will discuss the current understanding of PIK3CD, its potential as a drug target, and its role as a biomarker for cancer diagnosis and treatment.

Structure and Function

PIK3CD is a 21-kDa protein that is composed of a catalytic 伪尾纬 subunit and a regulatory 尾 subunit. The 伪尾纬 subunit consists of a catalytic alpha helix, a 尾 subunit, and a 纬 subunit. The 尾 subunit is responsible for the protein's unique 尾 -like structure, which is composed of a long N-terminus, a single transmembrane region, and a C-terminus. The 尾 subunit contains a unique IP3-binding site that allows it to regulate the activity of various cellular signaling pathways.

PIK3CD is regulated by various intracellular signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key target for many pharmaceuticals, including anti-cancer drugs. The PI3K /Akt signaling pathway is activated by the phosphorylation of the protein's catalytic active site, which leads to the formation of the phosphatidylinositol (PI) species. This formation is subsequent to the recruitment of the regulatory 尾 subunit to the protein, which activates the IP3- binding site and regulates the activity of the pathway.

Drug Target Potential

The PI3K/Akt signaling pathway is a widely studied pathway, and numerous inhibitors have been developed to target its various components. PIK3CD is an attractive drug target due to its unique structure, function, and regulation. The PI3K/Akt signaling pathway is a critical pathway involved in the regulation of cell growth, differentiation, and survival, making it an attractive target for cancer treatment.

PIK3CD has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, angiogenesis, and inflammation. Several studies have shown that inhibiting the PI3K/Akt signaling pathway can lead to the inhibition of various cellular processes that are associated with cancer growth and progression. Additionally, inhibitors of PIK3CD have been shown to be effective in preclinical models of cancer treatment, including inhibition of cancer cell growth, angiogenesis, and metastasis.

Biomarker Potential

PIK3CD has also been identified as a potential biomarker for cancer diagnosis and treatment. The PI3K/Akt signaling pathway is involved in the regulation of various cellular processes, including cell growth, apoptosis, and angiogenesis. As such, PIK3CD has been shown to be involved in the regulation of various cellular processes that are associated with cancer growth and progression.

The expression of PIK3CD has been shown to be associated with various cellular processes, including cell growth, apoptosis, and angiogenesis. Additionally, studies have shown that the expression of PIK3CD is regulated by various factors, including growth factors, cytokines, and chemokines. This Regulation suggests that PIK3CD may be a useful biomarker for cancer diagnosis and treatment by targeting therapies that can modulate its expression.

Conclusion

PIK3CD is a protein that plays a crucial role in

Protein Name: Phosphatidylinositol-4,5-bisphosphate 3-kinase Catalytic Subunit Delta

Functions: Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides (PubMed:9235916). Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Plays a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Plays important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity

The "PIK3CD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PIK3CD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets